Return On Equity
948%
Trailing 12 months · Through 30 Sep 2023
YoY relative change: -268%
Evelo Biosciences, Inc. financial metrics
Period Q3 2023 · Filed 09 Nov 2023
Key metrics snapshot
Return On Assets
-154%
Trailing 12 months · Through 30 Sep 2023
YoY relative change: +31%
Current Ratio
0.48x
Period-end balance · Through 30 Sep 2023
YoY relative change: -82%
Debt-to-equity
-2.41x
Period-end balance · Through 30 Sep 2023
YoY relative change: -129%
NetIncomeLoss YoY
31%
Trailing 12 months · Through 30 Sep 2023
Profitability
| Metric | Latest value | YoY relative change |
|---|---|---|
| Return On Equity |
948%
Trailing 12 months · 30 Sep 2023
|
-268% |
| Return On Assets |
-154%
Trailing 12 months · 30 Sep 2023
|
+30% |
Financial Health
| Metric | Latest value | YoY relative change |
|---|---|---|
| Current Ratio |
0.48x
Period-end balance · 30 Sep 2023
|
-82% |
| Debt-to-equity |
-2.41x
Period-end balance · 30 Sep 2023
|
-129% |
Growth
| Metric | Latest value | YoY relative change |
|---|---|---|
| NetIncomeLoss YoY |
31%
Trailing 12 months · 30 Sep 2023
|
Share Metrics
| Metric | Latest value | YoY relative change |
|---|---|---|
| Entity Common Stock, Shares Outstanding |
18,930,960
Period-end balance · 06 Nov 2023
|
-83% |
| Common Stock, Shares, Outstanding |
18,853,587
Period-end balance · 30 Sep 2023
|
-83% |
| Common Stock, Value, Issued |
$19,000
Period-end balance · 30 Sep 2023
|
-82% |
| Weighted Average Number of Shares Outstanding, Basic |
17,384,243
Reported period · 30 Sep 2023
|
+222% |
| Weighted Average Number of Shares Outstanding, Diluted |
17,384,243
Reported period · 30 Sep 2023
|
+222% |
Supporting Metrics
These supporting metrics stay fully source-backed for deeper research. Scan the latest value and reported period first, then open a metric page when you need the full filing trail.
| Metric | Latest value | YoY relative change |
|---|---|---|
| Accounts Payable, Current |
$526,000
Period-end balance · 30 Sep 2023
|
-66% |
| Accrued Liabilities, Current |
$4,550,000
Period-end balance · 30 Sep 2023
|
-64% |
| Assets |
$20,627,000
Period-end balance · 30 Sep 2023
|
-76% |
| Assets, Current |
$18,936,000
Period-end balance · 30 Sep 2023
|
-74% |
| Cash and Cash Equivalents, at Carrying Value |
$17,262,000
Period-end balance · 30 Sep 2023
|
-75% |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
$18,059,000
Period-end balance · 30 Sep 2023
|
-74% |
| Common Stock, Par or Stated Value Per Share |
0
Period-end balance · 30 Sep 2023
|
0% |
| Common Stock, Shares Authorized |
200,000,000
Period-end balance · 30 Sep 2023
|
0% |
| Common Stock, Shares, Issued |
18,853,587
Period-end balance · 30 Sep 2023
|
-83% |
| Contract with Customer, Liability, Noncurrent |
$7,500,000
Period-end balance · 30 Sep 2023
|
0% |
| Depreciation |
$1,588,000
Trailing 12 months · 30 Sep 2023
|
-24% |
| Earnings Per Share, Basic |
8
Trailing 12 months · 30 Sep 2023
|
+87% |
| Earnings Per Share, Diluted |
8
Trailing 12 months · 30 Sep 2023
|
+87% |
| General and Administrative Expense |
$20,852,000
Trailing 12 months · 30 Sep 2023
|
-38% |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest |
$81,444,000
Trailing 12 months · 30 Sep 2023
|
+32% |
| Income Tax Expense (Benefit) |
$905,000
Trailing 12 months · 30 Sep 2023
|
+87% |
| Liabilities |
$47,334,000
Period-end balance · 30 Sep 2023
|
-39% |
| Liabilities and Equity |
$20,627,000
Period-end balance · 30 Sep 2023
|
-76% |
| Liabilities, Current |
$39,761,000
Period-end balance · 30 Sep 2023
|
+48% |
| Nonoperating Income (Expense) |
$4,700,000
Trailing 12 months · 30 Sep 2023
|
-11% |
| Operating Income (Loss) |
$76,744,000
Trailing 12 months · 30 Sep 2023
|
+33% |
| Operating Lease, Liability |
$0
Period-end balance · 30 Sep 2023
|
-100% |
| Operating Lease, Liability, Current |
$0
Period-end balance · 30 Sep 2023
|
-100% |
| Operating Lease, Liability, Noncurrent |
$0
Period-end balance · 30 Sep 2023
|
-100% |
| Operating Lease, Right-of-Use Asset |
$0
Period-end balance · 30 Sep 2023
|
-100% |
| Operating Lease, Weighted Average Discount Rate, Percent |
0
Period-end balance · 30 Sep 2023
|
-105% |
| Other Assets, Noncurrent |
$797,000
Period-end balance · 30 Sep 2023
|
-31% |
| Other Liabilities, Noncurrent |
$73,000
Period-end balance · 30 Sep 2023
|
|
| Preferred Stock, Par or Stated Value Per Share |
0
Period-end balance · 30 Sep 2023
|
0% |
| Preferred Stock, Shares Authorized |
10,000,000
Period-end balance · 30 Sep 2023
|
0% |
| Preferred Stock, Shares Issued |
0
Period-end balance · 30 Sep 2023
|
|
| Preferred Stock, Shares Outstanding |
0
Period-end balance · 30 Sep 2023
|
|
| Property, Plant and Equipment, Gross |
$2,977,000
Period-end balance · 30 Sep 2023
|
|
| Property, Plant and Equipment, Net |
$894,000
Period-end balance · 30 Sep 2023
|
-84% |
| Research and Development Expense |
$53,483,000
Trailing 12 months · 30 Sep 2023
|
-34% |
| Retained Earnings (Accumulated Deficit) |
$588,030,000
Period-end balance · 30 Sep 2023
|
-16% |
| Share-based Payment Arrangement, Expense |
$11,171,000
Trailing 12 months · 30 Sep 2023
|
-31% |
| Stockholders' Equity Attributable to Parent |
$26,707,000
Period-end balance · 30 Sep 2023
|
-386% |
Comparisons, sources and research notes
Sources and sharing
Evelo Biosciences, Inc. Financial Facts
- Context
- Latest metrics period: Q3 2023
- Latest reported value
- Return On Equity 948%
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Open metric pages to inspect the reported history.
Tracking and update notes
Why revisit this company facts page
Company facts change as new 10-Q and 10-K filings update the latest reported period, headline values, and cross-company comparison context.
- Latest source-backed update
- Latest metrics period Q3 2023
- Why come back
- Use the next filing cycle to compare new facts against this baseline and then verify the detailed metric history.
- Current latest metrics period: Q3 2023.
- Most recent SEC facts end date on this page: 06 Nov 2023.
- Save this filer to return when the next filing-backed metric period changes the picture.
Freshness comes from the latest SEC company facts period available for this filer and the linked metric history pages.
Latest update
Latest update for Evelo Biosciences, Inc.
Latest financial period: Q3 2023. Reopen this facts page to verify the newest reported period against the prior baseline.
Update date
09 Nov 2023
Page type
Company facts
Latest period
Q3 2023
SEC-backed company facts were refreshed from filings filed on 09 Nov 2023.
Benchmark Context
How Return On Equity compares
Return On Equity is down about 268% versus the comparable prior period.
Compared with
Compared with Evelo Biosciences, Inc.'s recent history first. Same-industry peer context appears only when enough SEC-backed benchmark coverage exists.
Why this is notable
Return On Equity already has a self-history signal here, but same-industry benchmark context waits until the benchmark sample is strong enough.
- Latest comparable period on this page: Q3 2023.
- Peer context will appear when enough companies report a comparable value for this metric.
- Open the metric history first if you want to verify the exact period-to-period change.
Industry benchmark context uses SEC-reported values from the same methodology version. Latest periods may differ across companies.
How to read key metrics on this page
These short guides explain what the headline metrics mean, what to compare next, and where to open the live SEC-backed example for this company.
Plain-English Guide
How to read Net Income on this page
Net income is profit after operating costs, interest, taxes, and other non-operating items.
Why people care
It is the bottom-line profit figure many users recognize first, especially when they want to compare earnings with sales or cash flow.
How to read it
Use the same quarter or fiscal year comparison first, then check operating income or cash flow if the bottom line moved sharply.
Compare next
Compare it with operating income, EPS, and operating cash flow to see whether earnings are broad-based or driven by one-off items.
Net income can swing because of tax, financing, or accounting adjustments, so it is often less comparable than core operating metrics.
Open a live SEC-backed example
Filing notes and source
Key facts
- Evelo Biosciences, Inc. financial facts use SEC filings; any third-party reference is labeled separately.
- Latest metrics period on this page: Q3 2023.
- Headline metric: Return On Equity 948%.
Change
- Return On Equity YoY relative change: -268%.
- Most recent SEC facts end date: 06 Nov 2023.
Research use
- This gives a beginner-friendly first read before you inspect detailed formulas and metric tables.
- Metric cards link to SEC history; a third-party reference may use a different or unverified reporting period.
Evidence
Based on latest 10-Q/10-K
View source filing
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Open company facts to inspect the reported metric history.
Latest financial snapshot (2023-11-06) highlights Return On Equity 948.0%, Return On Assets -154.0%, and Current Ratio 0.48x.
Valuation Snapshot
SEC-only DCF estimate using a normalized free cash flow base, cash, debt, and reported share count when available.
No market comparison
No market comparison
Low confidence
Fair value per share
$76.97
Market price
n/a
PEG ratio
n/a
Enterprise value
$1.36B
Equity value
$1.34B
DCF fair value scenarios
Bear
$57.19
- Growth
- 1%
- Discount
- 11%
- Terminal
- 2%
Base
$76.97
- Growth
- 4%
- Discount
- 10%
- Terminal
- 2.5%
Bull
$108.10
- Growth
- 7%
- Discount
- 9%
- Terminal
- 3%
Base growth: DCF Growth Assumption.
Key valuation metrics
EV/Revenue
n/a
Market price market EV / SEC revenue
Market enterprise value is unavailable
EV/EBITDA
n/a
Market price market EV / SEC EBITDA
Market enterprise value is unavailable
P/E
n/a
Market price market price / SEC EPS
Market cap is unavailable
P/S
n/a
Market price market cap / SEC revenue
Market cap is unavailable
P/B
n/a
Market price market cap / SEC equity
Market cap is unavailable
PEG
n/a
P/E / DCF Growth Assumption
P/e or positive growth is unavailable
Core assumptions
- Projection
- 5 years
- FCF growth
- 4%
- Discount rate
- 10%
- Terminal growth
- 2.5%
SEC fact inputs
- DCF base FCF
- $93.06M
- Trailing SEC FCF
- Reported FCF
- $93.06M
- Net income
- $82.35M
- EBITDA
- $75.16M
- Cash
- $17.26M
- Debt
- n/a
- Equity
- $26.71M
- Shares
- 17,384,243
Data confidence notes
- Dcf base free cash flow: dcf base starts from trailing sec free cash flow
- Dcf base free cash flow: trailing free cash flow is not positive
- Dcf confidence is low for this sec-only free cash flow estimate
- Ticker missing for issuer
- Debt missing: equity value treats debt as 0
- Base free cash flow is negative; dcf output is mechanically computed but high risk
- Peg unavailable: market price is missing
Compare This Company Through SEC-backed Metrics
Use these links to compare Evelo Biosciences, Inc. against other SEC filers on the same metric, then verify the company history from the paired facts page.
NetIncomeLoss YoY
Latest value: 31%
Financial Quality Score
Transparent 0-100 scoring model based on profitability, financial health, and growth factors.
53.9/100
Caution Confidence medium
Return On Equity
948%
Metric score 100.0/100
Return On Assets
-154%
Metric score 0.0/100
Financial Health
- Current Ratio
- 0.48x
- Debt to Equity
- -2.41x
Strengths
Return On Equity and NetIncomeLoss YoY
Watchpoints
Return On Assets and Debt-to-equity
Calculation methodology and other links
How we score
This score is transparent and deterministic. We weight profitability, financial health, and growth metrics, then renormalize weights when SEC data is missing.
| Metric | Weight | V1 threshold |
|---|---|---|
| ROIC | 20 | 5% to 20% |
| ROE | 15 | 8% to 25% |
| ROA | 10 | 2% to 10% |
| Operating Margin | 5 | 5% to 25% |
| Current Ratio | 12 | 1.0x to 2.0x |
| Quick Ratio | 8 | 0.8x to 1.5x |
| Debt to Equity | 10 | 0.3x to 2.0x (lower is better) |
| Revenue YoY | 10 | -10% to +20% |
| Net Income YoY | 10 | -10% to +20% |
How Calculated (standard_v1)
Metrics are computed with a market-consensus convention designed for cross-portal comparability.
- Operating Income / Revenues using matching TTM or quarter periods; basis shown per metric
- Current Assets / Current Liabilities (latest instant quarter)
- (Current Assets - Inventory) / Current Liabilities; fallback: (Cash+Short-Term Investments + Accounts Receivable) / Current Liabilities
- Total Debt / Stockholders Equity (latest instant quarter; shared unit; freshest series)
- TTM Net Income / Average Equity (current quarter + same quarter previous year) / 2
- TTM Net Income / Average Assets (current quarter + same quarter previous year) / 2
- TTM NOPAT / Average Invested Capital, where NOPAT=Operating Income*(1-tax rate), Invested Capital=Equity+Total Debt-Cash & ST Investments
- Revenues YoY using available TTM or quarter comparison; basis shown per metric
- Net Income YoY using available TTM or quarter comparison; basis shown per metric
CIK / security context first